

Alkoxycarbonylation and Selective Deprotection of N-Silyl Derivatives of L-Arginine

Humphrey A. Moynihan* and Weiping Yu


School of Pharmacy and Chemistry, Liverpool John Moores University,
Byrom Street, Liverpool L3 3AF, United Kingdom

Received 10 February 1998; accepted 27 February 1998


Abstract: N^δ,N^ω,O-Tris(trialkylsilyl)-N^α-carbobenzyloxy-L-arginine can be prepared *in situ* from N^α-carbobenzyloxy-L-arginine. Treatment with alkyl chloroformates gives N^δ,N^ω-bis(alkyloxycarbonyl)-N^α-carbobenzyloxy-L-arginines, which can be converted into N^δ,N^ω-bis(alkyloxycarbonyl)-L-arginines by hydrogenation. © 1998 Elsevier Science Ltd. All rights reserved.

Guanidino-functionalised arginines are valuable in peptide synthesis¹ and as substrates or inhibitors of nitric oxide synthase (NOS)², the enzyme mediating the production of the key secondary messenger nitric oxide from arginine³. Selective protection of the guanidino group can be problematic⁴ while NOS inhibitors are usually obtained by multi-step synthesis from L-ornithine derivatives⁵. Most reported NOS inhibitors are guanidino-alkylated arginines, e.g., N^ω-methyl-², N^ω,N^ω-dimethyl-⁶, N^ω,N^{ω'}-dimethyl-⁶, and N^ω-allyl-L-arginine⁷, while some are guanidino-functionalised compounds, such as N^ω-amino- and N^ω-nitro-L-arginine⁸.

Synthetic methods which allow the direct introduction of functionality onto the arginine guanidino group could provide routes to novel, pharmacologically significant compounds. Jetten et. al. have reported a method for the controlled benzyloxycarbonylation of arginine⁴ via the intermediacy of N^α-carbobenzyloxy-N^δ,N^ω,O-tris(trimethylsilyl)-L-arginine (1). Reported herein is the application of this methodology to the preparation of orthogonally protected arginine derivatives, and the subsequent selective deprotection of these to give guanidino-alkoxycarbonylated arginines.



Solutions of N^α -carbobenzyloxy-L-arginine⁹ **2** and diisopropylethylamine (DiPEA) were treated with chlorotrimethylsilane, followed by addition of alkyl chloroformates. Use of methyl or isopropyl chloroformate gave the corresponding N^δ, N^ω -bis(alkyloxycarbonyl)- N^α -carbobenzyloxy-L-arginines, **3a** and **3b**, in 79% and 45% isolated¹⁰ yields, respectively. The reaction was also successful with methyl chlorothiolformate, giving N^δ, N^ω -bis(methylthiocarbonyl)- N^α -carbobenzyloxy-L-arginine **3c**, albeit in poor yield (25%). Use of cyanogen bromide or 3-chloroperoxybenzoic acid as electrophiles in the reaction gave no identifiable products. Use of more sterically demanding chlorotrialkylsilanes did not result in mono-alkoxycarbonylation of the guanidino group, even when only two equivalents of chlorosilane were used. Thus, treatment of **2** with 2.2 equivalents of tert-butylchlorodimethylsilane, followed by addition of benzyl chloroformate, gave $N^\alpha, N^\omega, N^\omega$ -tris(carbobenzyloxy)-L-arginine⁴ **3d** as the only product, in 45% yield, while treatment of **2** with 2.0 equivalents of tert-butylchlorodiphenylsilane, followed by methyl chloroformate, gave **3a** as the only product in 68%.




3a RX = MeO

3b RX = iPrO

3c RX = MeS

3d RX = PhCH₂O

Compounds **3a**, **3b** and the previously reported derivative N^δ, N^ω -bis(ethoxycarbonyl)- N^α -carbobenzyloxy-L-arginine⁹ **3e**, were subjected to catalytic hydrogenation¹¹ to give the N^δ, N^ω -bis(alkyloxycarbonyl)-L-arginines **4a**, **4b** and **4c**, in yields of 56%, 82% and 89% respectively.



As guanidino-functionalised derivatives of L-arginine, compounds **4a**, **4b** and **4c** have potential as NOS inhibitors. They could also be metabolised *in vivo* to L-arginine. However, only **4a** showed any observable conversion to arginine during *in vitro* experiments with *porcine pancreatic lipase*. Investigation of the biological activities of compounds **4a**, **4b** and **4c** is in progress.

ACKNOWLEDGEMENTS

The authors are grateful for the assistance of the EPSRC National Mass Spectrometry Service Centre and for financial support from the Royal Society of Chemistry Research Fund.

REFERENCES AND NOTES

1. Ramage, R.; Green, J.; Blake, A. J. *Tetrahedron* **1991**, *47*, 6353.
2. Rees, D. D.; Palmer, R. M. J.; Hodson, H. F.; Moncada, S. *Br. J. Pharmacol.* **1989**, *96*, 418.
3. Marletta, M. A. *J. Biol. Chem.* **1993**, *268*, 12231.
4. Jetten, M.; Peters, C. A. M.; van Nispen, J. W. F. N.; Ottenheijm, H. C. J. *Tetrahedron Lett.* **1991**, *32*, 6025.
5. Moynihan, H. A.; Roberts, S. M.; Weldon, H.; Allcock, G. H.; Anggard, E. E.; Warner, T. D. *J. Chem. Soc. Perkin Transactions 1* **1994**, 769.
6. Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. *Lancet* **1992**, *339*, 572.
7. Marletta, M. A.; Olken, N. M. *J. Med. Chem.* **1992**, *35*, 1137.
8. Gibson, A.; Mirzazadeh, S.; Hobbs, A. J.; Moores, P. K.; *Br. J. Pharmacol.* **1990**, *99*, 802.
9. Moynihan, H. A.; Yu, W. *Synth. Comm.* **1998**, *28*, 17.
10. The following general procedure was used to obtain compounds **3a,b,c** and **d**. Trialkylchlorosilane (3 eqv.) was added to a suspension of **2** and DiPEA (3 eqv.) in 1,2-dichloroethane under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 30 minutes and then at 40–50°C for 2 to 3 hours, after which it was cooled to 0°C and DiPEA (3 eqv.) added, followed by alkyl chloroformate (3 eqv.). The reaction mixture was stirred for several hours at ambient temperatures, after which it was washed with water, acidified with M hydrochloric acid (pH 2), extracted with

dichloromethane, dried over magnesium sulphate and the solvent evaporated. The product was isolated by silica gel chromatography using dichloromethane:methanol (10:1) as eluent.

3a: white crystalline solid; 135-136°C (MeOH); ν_{\max} (KBr)/cm⁻¹ 3990, 3328, 3287, 1746, 1731 and 1695; δ_{H} (200MHz, CDCl₃) 1.04 to 1.60 (4H, m, CH₂CH₂), 3.57 (3H, s, OCH₃), 3.70 (3H, s, OCH₃), 3.83 (2H, m, NCH₂), 4.20 (1H, m, CH), 4.99 (2H, s, OCH₂Ph), 5.79 (1H, d, NH), 7.18 to 7.23 (5H, m, ArH), 9.40 (2H, brs, NH x 2), 11.13 (1H, s, OH); Found: m/z (CI) (M + H)⁺ 425.1672.

C₁₈H₂₅N₄O₈ requires (M + H)⁺ 425.1672.

3b: oil; ν_{\max} (KBr)/cm⁻¹, 3390 and 1715; δ_{H} (200MHz, CDCl₃), 1.09 to 1.69 (4H, m, CH₂CH₂-), 1.22 to 1.29 (12H, m, CH₃ x 4), 3.92 (2H, m, NCH₂), 4.31 (1H, t, CH), 4.85 to 5.03 (2H, septet, CH(CH₃)₂ x 2), 5.08 (2H, s, CH₂Ph), 6.00 (1H, d, NH), 7.31 (5H, m, ArH), 9.4 (2H, brs, NH x 2); Found: m/z (CI) (M + H)⁺ 481.2340. C₂₂H₃₃N₄O₈ requires (M + H)⁺ 481.2298.

3c: yellow solid; 142-145°C; ν_{\max} (KBr)/cm⁻¹, 3376, 3292, 1730, 1695 and 1659; δ_{H} (200MHz, CDCl₃), 0.92 to 1.84 (4H, m, CH₂CH₂), 2.26 (3H, s, SCH₃), 2.35 (3H, s, SCH₃), 3.98 (2H, m, NCH₂), 4.40 (1H, t, CH), 5.16 (2H, s, CH₂Ph), 5.76 (1H, d, NH), 7.29-7.39 (5H, m, ArH), 9.42 (2H, brs, NH x 2); Found m/z (CI) (M + H)⁺ 457.1195. C₁₈H₂₅O₆N₄S₂ requires (M + H)⁺ 457.1215.

11. Compounds **4a**, **b** and **c** were obtained by reaction of compounds **3a**, **b** and **c** and 10% palladium on carbon catalyst in ethanol solution under a hydrogen atmosphere.

4a: light yellow solid, 205-207°C; ν_{\max} (KBr)/cm⁻¹ 3395, 1790, 1725 and 1698; δ_{H} (200MHz, CDCl₃), 1.22 to 1.73 (4H, m, CH₂CH₂), 3.03 to 4.2 (3H, m, CH and NCH₂), 3.66 (3H, s, CH₃O), 3.72 (3H, s, CH₃O), 6.20 (2H, brs, NH₂), 8.20 and 9.40 (2H, brs, NH x 2); Found m/z (FAB) (M + H)⁺ 291.1321. C₁₀H₁₉N₄O₆ requires (M + H)⁺ 219.1305.

4b: yellow oil; ν_{\max} (KBr)/cm⁻¹, 3406, 1786, 1719 and 1686; δ_{H} (200MHz, CDCl₃), 0.90 to 1.80 (4H, m, CH₂CH₂), 1.23 (12H, m, CH₃ x 4), 3.92 to 4.30 (3H, m, NCH₂ and CH), 4.95 (2H, m, CH(CH₃)₂ x 2), 7.05 to 7.24 (2H, m, NH₂), 9.40 (2H, brs, NH x 2); Found m/z (FAB) (M + H)⁺ 347.1966. C₁₄H₂₇N₄O₆ requires (M + H)⁺ 347.1931.

4c: white solid, 173-175°C; ν_{\max} (KBr)/cm⁻¹ 3394, 1725 and 1608; δ_{H} (200MHz, CDCl₃), 1.28 to 1.32 (6H, t, CH₃CH₂ x 2), 1.00 to 1.84 (4H, m, CH₂CH₂), 3.10 to 4.10 (3H, m, CH and NCH₂), 4.13 to 4.28 (4H, m, CH₃CH₂O x 2), 9.43 (2H, brs, NH x 2), Found m/z (FAB) (M + H)⁺ 319.1614. C₁₂H₂₃N₄O₆ requires (M + H)⁺ 319.1617.